Alkermes plc. — Director's Dealing 2024

Feb 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2024-02-26

Reporting Person: POPS RICHARD F (Director, Director and CEO, Alkermes plc)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-17	Employee Stock Option (Right to Buy)	$46.24	J	4599	Acquired	2024-03-03	Ordinary Shares (4599)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$69.83	J	3999	Acquired	2025-02-26	Ordinary Shares (3999)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$31.64	J	5999	Acquired	2026-02-28	Ordinary Shares (5999)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$53.50	J	3999	Acquired	2027-02-17	Ordinary Shares (3999)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$65.94	J	5899	Acquired	2028-02-16	Ordinary Shares (5899)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$31.93	J	2419	Acquired	2029-02-21	Ordinary Shares (2419)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$31.93	J	7644	Acquired	2029-02-21	Ordinary Shares (7644)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$20.03	J	7168	Acquired	2030-02-20	Ordinary Shares (7168)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$19.34	J	6843	Acquired	2031-02-22	Ordinary Shares (6843)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$24.59	J	5980	Acquired	2032-02-18	Ordinary Shares (5980)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$26.82	J	5697	Acquired	2033-02-23	Ordinary Shares (5697)	Direct
2024-02-26	Employee Stock Option (Right to Buy)	$30.04	A	274328	Acquired	2034-02-26	Ordinary Shares (274328)	Direct

Footnotes

F1: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2: These options are fully vested in accordance with their terms.

F3: Shares underlying the stock option award shall not vest and become exercisable unless and until the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, is fifty U.S. Dollars (US$50.00) or higher for thirty (30) consecutive trading days during the term of the award (the "performance criteria"). Subject to achievement of the performance criteria, the shares underlying the stock option award shall vest in four equal annual installments commencing on 2/21/2020. This award expires ten years from the date of grant.

F4: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

F5: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

F6: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

F7: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

F8: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/26/2025.